3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
4
Completed
3
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Hodgkin Disease
8
Lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Mycosis Fungoides
1
Lymphomatoid Papulosis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphatic Diseases
1
Leukemia
1
Immunoblastic Lymphadenopathy
1
Hematologic Diseases
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Rituximab
32
Cyclophosphamide
28
Lenalidomide
19
Prednisone
16
Doxorubicin
16
Vincristine
14
Etoposide
11
CT-P10
11
Gemcitabine
9
polatuzumab vedotin
8
Oxaliplatin
7
ibrutinib
6
glofitamab
6
fludarabine
6
acalabrutinib
6
Magnetic Resonance Spectroscopy
6
Ifosfamide
6
Carboplatin
6
tafasitamab
5
prednylidene
5
pembrolizumab
5
obinutuzumab
5
deltacortene
5
Specimen Handling
5
R-CHOP protocol
5
Nivolumab
5
Biopsy
5
venetoclax
4
fludarabine phosphate
4
selinexor
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma, Large B-Cell, Diffuse
×
Brentuximab Vedotin
×
Clear all
NCT04404283
2026-04-20
ECHELON-3
Seagen Inc.
Phase 3
Active not recruiting
239 enrolled
1 FDA
NCT02734771
2025-08-12
BV mini CHP
University of Rochester
Phase 2
Active not recruiting
24 enrolled